Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Diana L. Hanna
Observed names:
D Hanna,
D L Hanna,
D. Hanna,
D.L. Hanna,
Diana Hanna,
Diana L Hanna,
Hanna, Diana L.
show all 7
Institutions:
University of Southern California,
USC Norris Comprehensive Cancer Center
Observed institutions:
University of Southern California,
Hoag Memorial Hospital Presbyterian,
University of Graz,
Medical University of Graz,
Keck Hospital of USC,
USC Norris Comprehensive Cancer Center,
UC Davis Comprehensive Cancer Center,
Azusa Pacific University
show all 8
ORCID:
0000-0003-2681-5032
Observed ORCID:
0000-0003-2681-5032
OpenAlex ID:
A5102929792
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
2022
·
Funda Meric-Bernstam
, Muralidhar Beeram
, et al.
·
The Lancet Oncology
·
200
Impact of sex on the survival of patients with hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results analysis
2014
·
Dongyun Yang
, Diana L. Hanna
, et al.
·
Cancer
·
145
PDF
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
2016
·
Christian Dittrich
, Michael Kosty
, et al.
·
ESMO Open
·
129
PDF
Molecular Pathways: Cachexia Signaling—A Targeted Approach to Cancer Treatment
2016
·
Yuji Miyamoto
, Diana L. Hanna
, et al.
·
Clinical Cancer Research
·
109
The Importance of Understanding the Stages of COVID-19 in Treatment and Trials
2021
·
António Lobo-Ferreira
, April Amstrong
, et al.
·
Aids Reviews
·
92
Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
2018
·
Funda Meric-Bernstam
, Murali Beeram
, et al.
·
Journal of Clinical Oncology
·
86
Cabozantinib: An evolving therapy for hepatocellular carcinoma
2021
·
Anthony B. El-Khoueiry
, Diana L. Hanna
, et al.
·
Cancer Treatment Reviews
·
80
PDF
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
2022
·
Brandon M. Huffman
, Vasily N. Aushev
, et al.
·
JCO Precision Oncology
·
79
PDF
Colorectal cancer: epigenetic alterations and their clinical implications
2017
·
Alberto Puccini
, Martin D. Berger
, et al.
·
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
·
75
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
2021
·
Funda Meric-Bernstam
, Diana L. Hanna
, et al.
·
Journal of Clinical Oncology
·
66
Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients
2016
·
Y Ning
, W Zhang
, et al.
·
The Pharmacogenomics Journal
·
49
Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma
2024
·
Gregory P Botta
, Maen Abdelrahim
, et al.
·
The Oncologist
·
46
Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy
2014
·
M K H Maus
, D L Hanna
, et al.
·
The Pharmacogenomics Journal
·
44
Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
2013
·
Yan Ning
, Armin Gerger
, et al.
·
Molecular Cancer Therapeutics
·
41
PDF
Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.
2021
·
Funda Meric-Bernstam
, Erika P. Hamilton
, et al.
·
Journal of Clinical Oncology
·
40
Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach
2015
·
Yan Ning
, Diana L. Hanna
, et al.
·
Molecular Cancer Therapeutics
·
39
Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012
2016
·
Martin D. Berger
, Dongyun Yang
, et al.
·
Oncotarget
·
35
PDF
Biomolecular markers of cancer-associated thromboembolism
2013
·
Diana L. Hanna
, Richard H. White
, et al.
·
Critical Reviews in Oncology/Hematology
·
34
The time to offer treatments for COVID-19
2021
·
Binh T. Ngo
, Paul Marik
, et al.
·
Expert Opinion on Investigational Drugs
·
33
PDF
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
2017
·
Martin D. Berger
, Sebastian Stintzing
, et al.
·
Clinical Cancer Research
·
29
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials
2017
·
Martin D. Berger
, Shinichi Yamauchi
, et al.
·
European Journal of Cancer
·
28
DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer
2017
·
Charité N. Ricker
, Diana L. Hanna
, et al.
·
Cancer
·
27
PDF
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy
2016
·
Satoshi Matsusaka
, Diana L. Hanna
, et al.
·
Clinical Cancer Research
·
25
Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer.
2023
·
Stacey A. Cohen
, Pashtoon Murtaza Kasi
, et al.
·
Journal of Clinical Oncology
·
22
Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study
2022
·
Philippe L Bedard
, Seock-Ah Im
, et al.
·
Cancer Research
·
19
Show more works
View as search
Works count:
197
Citation count:
1,965
H-index:
23
I10-index:
43
Year
Topic
Type
